Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Mana Momenilandi, Romain Lévy, Steicy Sobrino, Jingwei Li, Chantal Lagresle-Peyrou, Hossein Esmaeilzadeh, Antoine Fayand, Corentin Le Floc'h, Antoine Guérin, Erika Della Mina, Debra Shearer, Ottavia M Delmonte, Ahmad Yatim, Kevin Mulder, Mathieu Mancini, Darawan Rinchai, Adeline Denis, Anna-Lena Neehus, Karla Balogh, Sarah Brendle, Hassan Rokni-Zadeh, Majid Changi-Ashtiani, Yoann Seeleuthner, Caroline Deswarte, Boris Bessot, Cassandre Cremades, Marie Materna, Axel Cederholm, Masato Ogishi, Quentin Philippot, Omer Beganovic, Mania Ackermann, Margareta Wuyts, Taushif Khan, Sébastien Fouéré, Florian Herms, Johan Chanal, Boaz Palterer, Julie Bruneau, Thierry J Molina, Stéphanie Leclerc-Mercier, Jean-Luc Prétet, Leila Youssefian, Hassan Vahidnezhad, Nima Parvaneh, Kristl G Claeys, Rik Schrijvers, Marine Luka, Philippe Pérot, Jacques Fourgeaud, Céline Nourrisson, Philippe Poirier, Emmanuelle Jouanguy, Stéphanie Boisson-Dupuis, Jacinta Bustamante, Luigi D Notarangelo, Neil Christensen, Nils Landegren, Laurent Abel, Nico Marr, Emmanuelle Six, David Langlais, Tim Waterboer, Florent Ginhoux, Cindy S Ma, Stuart G Tangye, Isabelle Meyts, Nico Lachmann, Jiafen Hu, Mohammad Shahrooei, Xavier Bossuyt, Jean-Laurent Casanova, Vivien Béziat
FMS-related tyrosine kinase 3 ligand (FLT3L), encoded by FLT3LG, is a hematopoietic factor essential for the development of natural killer (NK) cells, B cells, and dendritic cells (DCs) in mice. We describe three humans homozygous for a loss-of-function FLT3LG variant with a history of various recurrent infections, including severe cutaneous warts. The patients' bone marrow (BM) was hypoplastic, with low levels of hematopoietic progenitors, particularly myeloid and B cell precursors. Counts of B cells, monocytes, and DCs were low in the patients' blood, whereas the other blood subsets, including NK cells, were affected only moderately, if at all...
May 2, 2024: Cell
#2
JOURNAL ARTICLE
Paul Prunotto, Pauline Marie, Laurent Lebouvier, Yannick Hommet, Denis Vivien, Carine Ali
Recombinant tissue-type plasminogen activator (r-tPA/Actilyse) stands as the prevailing pharmacological solution for treating ischemic stroke patients, of whom because their endogenous circulating tPA alone is not sufficient to rescue reperfusion and to promote favorable outcome. Beyond the tPA contributed by circulating endothelial cells and hepatocytes, neurons also express tPA, sparking debates regarding its impact on neuronal fate ranging from pro-survival to neurotoxic properties. In order to investigate the role of neuronal tPA during brain injuries, we developed models leading to its conditional deletion in neurons, employing AAV9-pPlat-GFP and AAV9-pPlat-Cre-GFP along with tPA floxed mice...
April 12, 2024: Cell Death & Disease
#3
JOURNAL ARTICLE
Erwan Baudron, Sara Martinez de Lizarrondo, Maxime Gauberti, Barbara Delaunay-Piednoir, Antoine P Fournier, Denis Vivien, Fabian Docagne, Isabelle Bardou
INTRODUCTION: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system. Recent evidence suggests that lymphocyte trafficking in the intestines could play a key role in its etiology. Nevertheless, it is not clear how intestinal tissue is involved in the disease onset nor its evolution. In the present study, we aimed to evaluate intestinal inflammation dynamic throughout the disease course and its potential impact on disease progression. METHODS: We used tissue immunophenotyping (immunohistofluorescence and flow cytometry) and a recently described molecular magnetic resonance imaging (MRI) method targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1) to assess intestinal inflammation in vivo in two distinct animal models of MS (Experimental Autoimmune Encephalomyelitis - EAE) at several time points of disease progression...
April 9, 2024: Brain, Behavior, and Immunity
#4
JOURNAL ARTICLE
Mario Villa-González, Marina Rubio, Gerardo Martín-López, Paula R Mallavibarrena, Laura Vallés-Saiz, Denis Vivien, Francisco Wandosell, Maria José Pérez-Álvarez
Ischemic stroke is a sudden and acute disease characterized by neuronal death, increment of reactive gliosis (reactive microglia and astrocytes), and a severe inflammatory process. Neuroinflammation is an early event after cerebral ischemia, with microglia playing a leading role. Reactive microglia involve functional and morphological changes that drive a wide variety of phenotypes. In this context, deciphering the molecular mechanisms underlying such reactive microglial is essential to devise strategies to protect neurons and maintain certain brain functions affected by early neuroinflammation after ischemia...
April 6, 2024: Biology Direct
#5
JOURNAL ARTICLE
Martina Glavan, Ana Jelic, Damien Levard, Juhana Frösen, Sara Keränen, Bart A A Franx, Ana-Rita Bras, Estelle R Louet, Ádám Dénes, Mario Merlini, Denis Vivien, Marina Rubio
Intracerebral aneurysms (IAs) are pathological dilatations of cerebral arteries whose rupture leads to subarachnoid hemorrhage, a significant cause of disability and death. Inflammation is recognized as a critical contributor to the formation, growth, and rupture of IAs; however, its precise actors have not yet been fully elucidated. Here, we report CNS-associated macrophages (CAMs), also known as border-associated macrophages, as one of the key players in IA pathogenesis, acting as critical mediators of inflammatory processes related to IA ruptures...
March 18, 2024: Acta Neuropathologica Communications
#6
JOURNAL ARTICLE
Patrick-Brian Bielawski, Issan Zhang, Clara Correa-Paz, Francisco Campos, Martina Migliavacca, Ester Polo, Pablo Del Pino, Beatriz Pelaz, Denis Vivien, Dusica Maysinger
While stroke represents one of the main causes of death worldwide, available effective drug treatment options remain limited to classic thrombolysis with recombinant tissue plasminogen activator (rtPA) for arterial-clot occlusion. Following stroke, multiple pathways become engaged in producing a vicious proinflammatory cycle through the release of damage-associated molecular patterns (DAMPs) such as high-mobility group box 1 (HMGB1) and heat shock protein 70 kDa (HSP72). HMGB1, in particular, can activate proinflammatory cytokine production when acetylated (AcHMGB1), a form that prefers cytosolic localization and extracellular release...
March 8, 2024: ACS Pharmacology & Translational Science
#7
JOURNAL ARTICLE
Lydia B Munns, Harriet Demnitz-King, Claire André, Stéphane Rehel, Valentin Ourry, Vincent de La Sayette, Denis Vivien, Gaël Chételat, Géraldine Rauchs, Natalie L Marchant
OBJECTIVE: Poor sleep and high levels of repetitive negative thinking (RNT), including future-directed (ie, worry) and past-directed (ie, brooding) negative thoughts, have been associated with markers of dementia risk. The relationship between RNT and sleep health in older adults is unknown. This study aimed to investigate this association and its specificities including multiple dimensions of objective and subjective sleep. METHODS: This study used a cross sectional quantitative design with baseline data from 127 cognitively healthy older adults (mean age 69...
2024: Nature and Science of Sleep
#8
JOURNAL ARTICLE
Clement Gakuba, Alexandru-Daniel Dumitrascu, Pierre-Emmanuel Marson, Damien Legallois, Jean-Luc Hanouz, Denis Vivien, Sara Martinez De Lizarrondo, Maxime Gauberti, Damiano Cerasuolo
Multimers of von Willebrand factor (VWF) play a critical role in various processes inducing morbidity and mortality in cardiovascular risk patients. With the ability to reduce VWF multimers, N-acetylcysteine (NAC) could reduce mortality in patients undergoing coronary catheterization or cardiac surgery. However, its impact in perioperative period has never been studied so far in regard of its potential cardiovascular benefits. Then, four databases were searched for randomized controlled trials that compared in-hospital mortality between an experimental group, with NAC, and a control group without NAC, in patients undergoing coronary catheterization or cardiac surgery...
March 6, 2024: Journal of Cardiovascular Pharmacology
#9
JOURNAL ARTICLE
Clara Correa-Paz, María Pérez-Mato, Mathys Bellemain-Sagnard, Marco González-Domínguez, Pauline Marie, Lara Pérez-Gayol, Esteban López-Arias, Lucia Del Pozo-Filíu, Sonia López-Amoedo, Ana Bugallo-Casal, María Luz Alonso-Alonso, María Candamo-Lourido, María Santamaría-Cadavid, Susana Arias-Rivas, Manuel Rodríguez-Yañez, Ramón Iglesias-Rey, José Castillo, Denis Vivien, Marina Rubio, Francisco Campos
Alteplase (rtPA) remains the standard thrombolytic drug for acute ischemic stroke. However, new rtPA-derived molecules, such as tenecteplase (TNK), with prolonged half-lives following a single bolus administration, have been developed. Although TNK is currently under clinical evaluation, the limited preclinical data highlight the need for additional studies to elucidate its benefits. The toxicities of rtPA and TNK were evaluated in endothelial cells, astrocytes, and neuronal cells. In addition, their in vivo efficacy was independently assessed at two research centers using an ischemic thromboembolic mouse model...
March 4, 2024: Journal of Cerebral Blood Flow and Metabolism
#10
JOURNAL ARTICLE
Nadine Felizitas Binder, Mohamad El Amki, Chaim Glück, William Middleham, Anna Maria Reuss, Adrien Bertolo, Patrick Thurner, Thomas Deffieux, Chryso Lambride, Robert Epp, Hannah-Lea Handelsmann, Philipp Baumgartner, Cyrille Orset, Philipp Bethge, Zsolt Kulcsar, Adriano Aguzzi, Mickael Tanter, Franca Schmid, Denis Vivien, Matthias Tasso Wyss, Andreas Luft, Michael Weller, Bruno Weber, Susanne Wegener
Recanalization is the mainstay of ischemic stroke treatment. However, even with timely clot removal, many stroke patients recover poorly. Leptomeningeal collaterals (LMCs) are pial anastomotic vessels with yet-unknown functions. We applied laser speckle imaging, ultrafast ultrasound, and two-photon microscopy in a thrombin-based mouse model of stroke and fibrinolytic treatment to show that LMCs maintain cerebral autoregulation and allow for gradual reperfusion, resulting in small infarcts. In mice with poor LMCs, distal arterial segments collapse, and deleterious hyperemia causes hemorrhage and mortality after recanalization...
February 16, 2024: Neuron
#11
JOURNAL ARTICLE
Célia Seillier, Léonie Lesec, Pauline Hélie, Charlotte Marie, Denis Vivien, Fabian Docagne, Brigitte Le Mauff, Olivier Toutirais
Tissue-plasminogen activator (tPA) is a serine protease well known for its fibrinolytic function. Recent studies indicate that tPA could also modulate inflammation via plasmin generation and/or by receptor mediated signalling in vitro. However, the contribution of tPA in inflammatory processes in vivo has not been fully addressed. Therefore, using tPA-deficient mice, we have analysed the effect of lipopolysaccharide (LPS) challenge on the phenotype of myeloid cells including neutrophils, macrophages and dendritic cells (DCs) in spleen...
February 14, 2024: Journal of Inflammation
#12
REVIEW
Adrià Dalmau Gasull, Martina Glavan, Sai K Reddy Samawar, Kishan Kapupara, Joe Kelk, Marina Rubio, Stefano Fumagalli, Lydia Sorokin, Denis Vivien, Marco Prinz
There are several cellular and acellular structural barriers associated with the brain interfaces, which include the dura, the leptomeninges, the perivascular space and the choroid plexus epithelium. Each structure is enriched by distinct myeloid populations, which mainly originate from erythromyeloid precursors (EMP) in the embryonic yolk sac and seed the CNS during embryogenesis. However, depending on the precise microanatomical environment, resident myeloid cells differ in their marker profile, turnover and the extent to which they can be replenished by blood-derived cells...
February 12, 2024: Acta Neuropathologica
#13
EDITORIAL
Carine Ali, Denis Vivien
No abstract text is available yet for this article.
January 30, 2024: Neuroscience
#14
JOURNAL ARTICLE
Jonathane Furon, Florent Lebrun, Mervé Yétim, Damien Levard, Pauline Marie, Cyrille Orset, Sara Martinez de Lizarrondo, Denis Vivien, Carine Ali
BACKGROUND: Intravenous injection of alteplase, a recombinant tPA (tissue-type plasminogen activator) as a thrombolytic agent has revolutionized ischemic stroke management. However, tPA is a more complex enzyme than expected, being for instance able to promote thrombolysis, but at the same time, also able to influence neuronal survival and to affect the integrity of the blood-brain barrier. Accordingly, the respective impact of endogenous tPA expressed/present in the brain parenchyma versus in the circulation during stroke remains debated...
March 2024: Stroke; a Journal of Cerebral Circulation
#15
JOURNAL ARTICLE
Billal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, Claire Mignard, Marie-Laure Golinski, Sébastien Calbo, Catherine Prost-Squarcioni, Bruno Labeille, Catherine Picard-Dahan, Guillaume Chaby, Marie-Aleth Richard, Emmanuelle Tancrede-Bohin, Sophie Duvert-Lehembre, Emmanuel Delaporte, Philippe Bernard, Frédéric Caux, Marina Alexandre, Philippe Musette, Saskia Ingen-Housz-Oro, Pierre Vabres, Gaëlle Quereux, Alain Dupuy, Sébastien Debarbieux, Martine Avenel-Audran, Michel D'Incan, Christophe Bédane, Nathalie Bénéton, Denis Jullien, Nicolas Dupin, Laurent Misery, Laurent Machet, Marie Beylot-Barry, Olivier Dereure, Bruno Sassolas, Jacques Benichou, Pascal Joly, Vivien Hébert
IMPORTANCE: The Ritux 3 trial demonstrated the short-term efficacy and safety of first-line treatment with rituximab compared with a standard corticosteroid regimen in pemphigus. No data on the long-term follow-up of patients who received rituximab as first line are available. OBJECTIVE: To assess the long-term efficacy and safety of the Ritux 3 treatment regimen. DESIGN, SETTING, AND PARTICIPANTS: This 7-year follow-up study of the Ritux 3 trial included patients with pemphigus from 25 dermatology departments in France from January 1, 2010, to December 31, 2015...
January 24, 2024: JAMA Dermatology
#16
JOURNAL ARTICLE
Pierre Champetier, Claire André, Stéphane Rehel, Valentin Ourry, Brigitte Landeau, Florence Mézenge, Daniel Roquet, Denis Vivien, Vincent de La Sayette, Gaël Chételat, Géraldine Rauchs
STUDY OBJECTIVES: In aging, reduced delta power (0.5-4 Hz) during N2 and N3 sleep has been associated with gray matter (GM) atrophy and hypometabolism within frontal regions. Some studies have also reported associations between N2 and N3 sleep delta power in specific sub-bands and amyloid pathology. Our objective was to better understand the relationships between spectral power in delta sub-bands during N2-N3 sleep and brain integrity using multimodal neuroimaging. METHODS: In-home polysomnography was performed in 127 cognitively unimpaired older adults (mean age ± SD: 69...
April 12, 2024: Sleep
#17
JOURNAL ARTICLE
Florent Lebrun, Damien Levard, Eloïse Lemarchand, Mervé Yetim, Jonathane Furon, Fanny Potzeha, Pauline Marie, Flavie Lesept, Manuel Blanc, Benoit Haelewyn, Marina Rubio, Annelise Letourneur, Nicolas Violle, Cyrille Orset, Denis Vivien
The pharmacological intervention for ischemic stroke hinges on intravenous administration of the recombinant tissue-type plasminogen activator (rtPA, Alteplase/Actilyse®) either as a standalone treatment or in conjunction with thrombectomy. However, despite its clinical significance, broader employment of rtPA is constrained due to the risk of hemorrhagic transformations (HTs). Furthermore, the presence of diabetes or chronic hyperglycemia is associated with an elevated risk of HT subsequent to thrombolysis...
January 8, 2024: Blood Advances
#18
JOURNAL ARTICLE
Martina Migliavacca, Clara Correa-Paz, María Pérez-Mato, Patrick-Brian Bielawski, Issan Zhang, Pauline Marie, Pablo Hervella, Marina Rubio, Dusica Maysinger, Denis Vivien, Pablo Del Pino, Beatriz Pelaz, Ester Polo, Francisco Campos
BACKGROUND: Intravenous administration of fibrinolytic drugs, such as recombinant tissue plasminogen activator (rtPA) is the standard treatment of acute thrombotic diseases. However, current fibrinolytics exhibit limited clinical efficacy because of their short plasma half-lives and risk of hemorrhagic transformations. Platelet membrane-based nanocarriers have received increasing attention for ischemic stroke therapies, as they have natural thrombus-targeting activity, can prolong half-life of the fibrinolytic therapy, and reduce side effects...
January 3, 2024: Journal of Nanobiotechnology
#19
JOURNAL ARTICLE
Bart Aa Franx, Florent Lebrun, Lois Chin Joe Kie, Thomas Deffieux, Denis Vivien, Thomas Bonnard, Rick M Dijkhuizen
Tomographic perfusion imaging techniques are integral to translational stroke research paradigms that advance our understanding of the disease. Functional ultrasound (fUS) is an emerging technique that informs on cerebral blood volume (CBV) through ultrasensitive Doppler and flow velocity (CBFv) through ultrafast localization microscopy. It is not known how experimental results compare with a classical CBV-probing technique such as dynamic susceptibility contrast-enhanced perfusion MRI (DSC-MRI). To that end, we assessed hemodynamics based on uUS (n = 6) or DSC-MRI (n = 7) before, during and up to three hours after 90-minute filament-induced middle cerebral artery occlusion (MCAO) in rats...
December 21, 2023: Journal of Cerebral Blood Flow and Metabolism
#20
JOURNAL ARTICLE
Louise Fournier, Myriam Abioui-Mourgues, Georges Chabouh, Rachida Aid, Thibault De La Taille, Olivier Couture, Denis Vivien, Cyrille Orset, Cédric Chauvierre
Systemic injection of thrombolytic drugs is the gold standard treatment for non-invasive blood clot resolution. The most serious risks associated with the intravenous injection of tissue plasminogen activator-like proteins are the bleeding complication and the dose related neurotoxicity. Indeed, the drug has to be injected in high concentrations due to its short half-life, the presence of its natural blood inhibitor (PAI-1) and the fast hepatic clearance (0.9 mg/kg in humans, 10 mg/kg in mouse models)...
November 8, 2023: Biomaterials
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
